Fort Sheridan Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$748K Sell
1,674
-328
-16% -$153K 0.09% 141
2025
Q4
$908K Hold
2,002
0.12% 115
2025
Q3
$784K Sell
2,002
-74
-4% -$30.9K 0.1% 123
2025
Q2
$924K Sell
2,076
-352
-14% -$162K 0.13% 112
2025
Q1
$1.18M Buy
2,428
+4
+0.2% +$1.86K 0.18% 81
2024
Q4
$976K Buy
2,424
+386
+19% +$179K 0.14% 105
2024
Q3
$948K Buy
2,038
+11
+0.5% +$5.28K 0.14% 101
2024
Q2
$950K Buy
2,027
+352
+21% +$153K 0.15% 93
2024
Q1
$700K Buy
1,675
+107
+7% +$45.2K 0.13% 105
2023
Q4
$638K Sell
1,568
-300
-16% -$111K 0.13% 107
2023
Q3
$650K Hold
1,868
0.15% 102
2023
Q2
$657K Hold
1,868
0.15% 98
2023
Q1
$589K Buy
1,868
+376
+25% +$113K 0.15% 101
2022
Q4
$431K Hold
1,492
0.14% 113
2022
Q3
$432K Hold
1,492
0.15% 110
2022
Q2
$421K Buy
1,492
+352
+31% +$94.2K 0.14% 110
2022
Q1
$298K Sell
1,140
-161
-12% -$38.2K 0.09% 142
2021
Q4
$286K Buy
+1,301
New +$253K 0.08% 158
2021
Q2
Sell
-1,151
Closed -$247K 192
2021
Q1
$247K Sell
1,151
-689
-37% -$151K 0.1% 132
2020
Q4
$435K Buy
+1,840
New +$422K 0.21% 66
2020
Q3
Sell
-700
Closed -$203K 118
2020
Q2
$203K Buy
+700
New +$190K 0.12% 96

Other funds holding VRTX

Fort Sheridan Advisors's VRTX Position: Q1 2026 in Review

Fort Sheridan Advisors reduced its Vertex Pharmaceuticals (VRTX) stake by 16% in Q1 2026, selling an estimated $153K and leaving 1,674 shares worth $748K. The position accounts for 0.09% of the portfolio, ranked #141.

Fort Sheridan Advisors first reported a position in VRTX in Q2 2020 and has held it in 21 quarters since. The position peaked at $1.18M in Q1 2025. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Fort Sheridan Advisors held 1,674 shares of Vertex Pharmaceuticals worth $748K as of Q1 2026.
  • Fort Sheridan Advisors sold 328 Vertex Pharmaceuticals shares in Q1 2026, an estimated $153K.
  • Vertex Pharmaceuticals made up 0.09% of Fort Sheridan Advisors's portfolio in Q1 2026, its #141 holding.
  • Fort Sheridan Advisors first reported a position in Vertex Pharmaceuticals in Q2 2020 and has held it in 21 quarters since.
  • Fort Sheridan Advisors's Vertex Pharmaceuticals position peaked at $1.18M in Q1 2025.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Fort Sheridan Advisors's 13F filing for Q1 2026, filed 6 May 2026.